Array BioPharma Inc. (NASDAQ:ARRY) CEO Ron Squarer sold 819,671 shares of Array BioPharma stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $10.86, for a total transaction of $8,901,627.06. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Array BioPharma Inc. (ARRY) traded down $0.13 during trading on Thursday, reaching $13.85. 1,079,391 shares of the company’s stock were exchanged, compared to its average volume of 4,057,614. The firm has a market capitalization of $2,810.00, a P/E ratio of -18.72 and a beta of 1.91. The company has a current ratio of 5.43, a quick ratio of 5.43 and a debt-to-equity ratio of 0.54. Array BioPharma Inc. has a 1 year low of $6.73 and a 1 year high of $14.13.
Array BioPharma (NASDAQ:ARRY) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, hitting analysts’ consensus estimates of ($0.22). The firm had revenue of $29.75 million during the quarter, compared to the consensus estimate of $33.74 million. Array BioPharma had a negative net margin of 89.30% and a negative return on equity of 158.70%. The firm’s revenue was down 24.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.20) earnings per share. research analysts predict that Array BioPharma Inc. will post -0.99 EPS for the current year.
A number of analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Array BioPharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 4th. Cantor Fitzgerald set a $15.00 price target on shares of Array BioPharma and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Jefferies Group raised their price target on shares of Array BioPharma to $13.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. BidaskClub raised shares of Array BioPharma from a “sell” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, SunTrust Banks reissued a “buy” rating and set a $16.00 price target on shares of Array BioPharma in a research report on Wednesday, November 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. Array BioPharma has an average rating of “Buy” and a consensus target price of $14.10.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://stocknewstimes.com/2018/01/11/insider-selling-array-biopharma-inc-arry-ceo-sells-819671-shares-of-stock.html.
Array BioPharma Company Profile
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Receive News & Ratings for Array BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.